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phonates are widely used and are considered an effective intervention for risk reduc-
tion of postmenopausal fractures. The 100% out-of-pocket purchase of medicines by 
patients is a reality in Brazil. So, a study under patient perspective is an important 
tool to help decision-making. OBJECTIVES: The present study was conducted to 
compare the cost of bisphosphonates used for risk reduction of post-menopause ver-
tebral and non-vertebral fractures under patient perspective in Brazil. METHODS: 
The most important bisphosphonates in the Brazilian market to patients are ibandro-
nate (oral and IV), zolendronate, alendronate and risendronate. There are no head-
to-head clinical trials comparing all the compounds. Studies of ibandronate [Eisman, 
2008] and zolendronate [McClung, 2007] demonstrated their non-inferiority against 
oral bisphosphonates. Therefore, a cost-minimization approach was taken. Drug 
consumer prices were obtained from ofﬁcial public sources [Kairos magazine, May 
2009]. Since the time horizon of this analysis is one-year, no discount rate was utilized. 
Costs are presented in Brazilian Reais (US$1.00^R$2.00 in May 2009). RESULTS: 
Total cost per patient was R$1534.36 for IV ibandronate, R$1685.83 for alendronate, 
R$1941.17 for oral ibandronate, R$1951,26 for zolendronate and R$2354.52 for 
risendronate. CONCLUSIONS: Findings suggest that IV ibandronate is a cost-saving 
therapy with potential of reducing the total treatment cost per patient from 9% up 
to 35%, when compared to alendronate and risendronate respectively, considering 
patient perspective in Brazil.
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OBJECTIVES: To compare the costs of treating osteoarthritis (OA) pain using com-
bination tramadol/paracetamol tablets, Non-Steroidal Anti-Inﬂammatory Agents 
(NSAIDs) alone or NSAIDs plus proton pump inhibitors (PPIs) from the perspective 
of the Spanish National Health System. METHODS: A decision-analytical model was 
constructed to analyse the cost outcomes of the three treatment strategies over 6 
months. A cost-minimisation approach was used, which considered data related to 
resource utilisation, medication costs and costs for the treatment of adverse events. 
Data, derived mainly from the clinical literature, were supplemented by inputs from 
a Delphi panel as well as ofﬁcial price and tariff lists. The base-case analysis considered 
direct medical costs, including those for treating gastrointestinal (GI) and cardiovas-
cular (CV) adverse events. Separate scenario analyses explored costs of NSAID-based 
regimens when renal events attributable to NSAIDs were considered. Univariate sen-
sitivity analysis and scenario analysis considering different levels of adverse events, 
risk and adverse events costs where also carried out. RESULTS: In the base-case 
analysis, costs for 6 months´treatment of OA pain using tramadol/paracetamol were 
a232.86 compared with a274.60 for NSAIDs  PPIs and a133.75 for NSAIDs alone. 
This provided a cost saving of a41.74 per patient over 6 months for tramadol/
paracetamol compared with NSAIDs  PPIs and a cost increase of a99.11 compared 
with NSAIDs alone. When renal adverse events of NSAIDs were considered, trama-
dol/paracetamol was cost saving compared with all NSAID-based regimens (saving 
a140.02 vs NSAIDs alone, a280.86 vs. NSAIDs  PPIs). Sensitivity analysis conﬁrmed 
these results using extreme values of probabilities and unit costs for all options. 
CONCLUSIONS: Tramadol/paracetamol is cost saving compared with NSAIDs  PPIs 
for the treatment of OA pain over a period of 6six months. Tramadol/paracetamol is 
also cost saving compared with treatment with NSAIDs alone if considering renal 
adverse events.
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OBJECTIVES: To evaluate the cost-effectiveness of a treatment sequence including 
tocilizumab 8mg/kg vs the standard treatment sequence (STS) currently used in moder-
ate/severe RA patients following inadequate response to previous DMARD therapy in 
Italy. METHODS: A cost-utility analysis was conducted from a payor’s perspective. 
An individual simulation model was employed to project lifetime cost, and QALYs 
for 10,000 patients. The model compared the STS (etanercept, adalimumab, ritux-
imab, abatacept, and palliative care) with a sequence in which tocilizumab replaces 
etanercept. Patient characteristics (age, HAQ-DI score, sex and weight) were based on 
data from three phase III clinical trials. A mixed treatment comparison was used to 
estimate ACR response rates for each of the treatments in both sequences. Patient data 
from the clinical trials were used to model the relationship between HAQ-DI scores 
and EuroQol (EQ-5D) utilities. Resource utilization, and treatment costs (acquisition, 
administration, and monitoring) were obtained from the literature and the Italian 
formulary. Clinical trial data and available literature provided a basis for ﬁtting 
appropriate distributions to the model parameters in order to perform probabilistic 
sensitivity analysis (PSA). Costs and QALYs were discounted at 3.5%. RESULTS: The 
model estimated that the treatment sequence including tocilizumab produced 0.275 
QALYs more than the standard sequence at additional cost of a984, resulting in an 
ICER of a3586 per QALY. Several sensitivity and scenario analyses showed that the 
model is robust to alternative parameter selections. The results of PSA (1000 samples) 
demonstrated that the ICER for the tocilizumab sequence is always below a threshold 
of a50,000. CONCLUSIONS: In patients who have failed DMARD therapy, the 
model consistently predicts that starting treatment with tocilizumab is cost-effective 
compared to the standard treatment sequence in Italy. The analysis suggests that 
switching between biologic treatments with different modes of action can be a cost-
effective option vs. TNF cycling.
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OBJECTIVES: The purpose of this study was to estimate the cost-utility of a topical 
formulation of diclofenac compared to a standard diclofenac oral preparation in 
patients treated for osteoarthritis of the knee having risk factors for gastrointestinal 
complications (older age or previous GI events). METHODS: For this cost-utility 
analysis, a Markov model was developed based on the model by Maetzel et al.. The 
analysis was performed according to a Minister of Health perspective over a ﬁve-year 
horizon. The model takes into account incidence of gastrointestinal events, incidence 
of complicated gastrointestinal events (perforation and bleeding, mortality), incidence 
of skin related adverse events and use of PPI. Utility estimates associated with each 
health states were taken from published sources. Cost of medications and costs associ-
ated with the management of gastrointestinal events (hospitalisation, emergency visits, 
physician’s visits, endoscopy, etc.) were considered. RESULTS: Cost-utility ratios are 
$39,342 per QALY for patients 65 to 74 years old, $22,019 for those 75 years old 
and more and $24,141 for patients with previous GI events. Base case results were 
robust to various deterministic and probabilistic sensitivity analyses. CONCLU-
SIONS: Topical diclofenac is a cost-effective alternative to oral diclofenac for patients 
having risk factors for GI complications.
PMS56
COST-UTILITY OF AUTOLOGOUS CHONDROCYTES IMPLANTATION 
USING CHONDROCELECT® IN SYMPTOMATIC KNEE CARTILAGE 
DAMAGE IN BELGIUM
Gerlier L1, Lamotte M1, Wille M2, Dubois D3
1IMS Health, Brussels, Belgium, 2TiGenix NV, Leuven, Belgium, 3Patient Value Solutions, 
Huldenberg, Belgium
OBJECTIVES: Knee cartilage defects increase the risk of osteoarthritis and prosthesis. 
No standard treatment exists. ChondroCelect® is used in autologous chondrocytes 
implantation (ACI) to treat symptomatic knee cartilage defect. Its efﬁcacy and safety 
was demonstrated in a randomized controlled trial (TIG/ACT/01) vs. the surgical 
procedure microfracture. This study investigated the cost-utility of ChondroCelect® in 
Belgium. METHODS: A decision tree comparing ChondroCelect® to microfracture 
over a 40-year horizon was developed. Key variables were provided by the TIG/
ACT/01 trial (3-year clinical success using the Knee injury and Osteoarthritis Outcome 
Score [KOOS], 1-year structural repair/presence of hyaline [ good quality] cartilage 
based on International Cartilage Repair Society visual item [ICRS II] and utility scores 
by health state derived from the SF-36 questionnaire) and literature (incidence of 
osteoarthritis starting 15 years post-surgery [model assumption], incidence of total 
knee replacement [at 20 years] and prosthesis revision [at 35 years]). A patient chart 
review (n  82 patients) provided follow-up costs by surgery outcome. National tariffs 
were applied to medical resources used (Societal perspective). In accordance to Belgian 
guidelines annual discounting was applied to costs (3%) and effects (1.5%). RESULTS: 
The key TIG/ACT/01 outcomes with Chondrocelect® vs. microfracture were clinical 
success (KOOS) in 83% vs. 61% (p  0.018) and presence of hyaline cartilage (ICRS 
II) in 45% vs. 23% (p  0.010). The incremental cost/QALY gained was a29,397. 
The most sensitive parameters were the proportion of patients with hyaline cartilage 
and the correlation between hyaline cartilage formation and later avoidance of osteo-
arthritis. Probabilistic sensitivity analysis showed robustness of the results, with 60% 
of the simulations falling below a willingness-to-pay of a32,400/QALY (Belgian GDP/
capita, 2008). CONCLUSIONS: A high quality cartilage is expected to translate into 
reduced osteoarthritis development and thus fewer knee replacements. Corresponding 
mid/long term QALYs gained and cost savings made ChondroCelect® use in ACI 
cost-effective in Belgium.
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OBJECTIVES: Japan has been facing an aging society and the burden of illness for 
vertebral compression fracture (VCF) has become a signiﬁcant issue from an economic 
point of view as well as clinical point of view. Reduction of pain and improvement 
